DALLAS, February 26, 2015 /PRNewswire/ --
LifeScienceIndustryResearch.com adds Global Pharma US & EU Outlook 2015: First -In- Class Innovations and Cost Optimization Plays Major Role In Shaping Up Business for Large Cap Pharmaceutical Companies research report to the pharmaceuticals intelligence collection of its store.
According to this Global Pharma US & EU Outlook 2015 report, strategy diversification stays divested as productivity measurements, divestment of non-core assets result in healthy cash position and will accelerate next wave of targeted acquisition. In the recent years several new therapies have been approved in the area of diabetes (SGLT-2, GLP-1 agonists), Multiple Sclerosis, HCV, melanoma and breast cancer from major pharmaceutical companies. Many of them are expected to reach multibillion dollars peak sales in the near-term which is likely to compensate the patent expiry loss in top-line revenue. Novel mechanisms like anti-PD1, anti-PCSK9 and CDK inhibitors have also got exclusive attention by large cap Pharma companies. Most companies are in race to acquire assets in these hot therapy areas. Companies who already have these assets are investing heavily in clinical development programs. The interest in pursuing opportunities in Oncology therapy is unhindered for all major Pharma companies. Research investments in oncology likely to continue for several more years due to the significant unmet need exist in this area. Complete report is available at http://www.lifescienceindustryresearch.com/global-pharma-us-eu-outlook-2015-first-in-class-innovations-and-cost-optimization-plays-major-role-in-shaping-up-business-for-large-cap-pharmaceutical-companies.html .
For a few companies, patent expiry impact continues to haunt the top-line and they are finding it difficult to replace declining sales with Proprietary pipeline products. Beyond 2013, the impact of patent loss will further aggravate the revenue decline. They have chosen strategies of prioritization pipeline assets, cost efficiency measures, divestment of non-core assets which yield poor margins and increase focus on therapy areas where they have already proven its mettle. Increase in dividend payout and share repurchase are some near term measures where they are actively participating. Gain in financial strength through divestment of non-core assets (OTC, Animal Health, Consumer health, Diagnostics) will be utilized in pursuing opportunities in high margin therapy areas. At the same time it has becoming more difficult to find such lucrative assets because they are scarce and if available are trading at very high premium in speculation of getting acquired (ex. Roche-Alexion). Going forward, Economies of Scale will also play a major role in swapping the non-core business among major pharma including Vaccines, OTC and animal health to improve margins.
Global Pharma continues to remain attractive due to management efforts on the restructuring of entire business model, cost efficiency measures, de-consolidation, acquisition of high value targeted assets, share repurchase program and dividend policy.
Companies Mentioned in this Global Pharma US & EU Outlook 2015 report include AstraZeneca, Merck, Merck KGaA, Novartis, Novo Nordisk and GlaxoSmithKline. Order a copy of this research at http://www.lifescienceindustryresearch.com/purchase?rname=35177 .
On similar lines, a new 2015 research on Global Rising Stars Outlook 2015 says Innovative Therapies for treating diseases are being sought after with fresh vigor as new targets, approaches and biology is discovered. One field which is poised to bring a paradigm change in the way diseases are treated in the next decades is the Stem cell therapy/Regenerative Medicine space. The number of companies and products in the clinic has reached a critical mass warranting a close watch for those interested in keeping pace with the development of new medicines. The Regenerative medicine Universe is large and new companies are being added to it rapidly. As a result we have used some filters to select a few names for a detailed coverage in our Outlook this year. Key Criteria for Our Selection are:-
. Uniqueness of the Technology platform and the ability to scale up
commercially in case of positive outcome of products in the pipeline
. Pipeline and clinical data analysis
. Marketed product and commercial tie up.
. Robustness of the
Management, financial and business model.
Companies Mentioned in this research include CESCA Therapeutics,OCATA Therapeutics ,Orgenesis, TiGenix, Pluristem Therapeutics ,Mesobalst Ltd, Mesobalst, Medipost, JCR Pharmaceuticals, Japan Tissue Engineering, Connexios, Bugworks, Cellworks and Tergene. Order a copy of this report at http://www.lifescienceindustryresearch.com/purchase?rname=35180 .
Explore more reports on the pharmaceuticals market at http://www.lifescienceindustryresearch.com/category/pharmaceuticals .
About Us:
Life Science Industry Research brings to you to the latest reports in market research on Biotechnology, Diagnostics, Healthcare, Medical Devices and Pharmaceuticals segments from leading research publishers across the globe. These reports also cover data and information on sub-segments and sectors under these life sciences categories.
Contact:
Siju K.
TX,Dallas North- Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel: +1-888-391-5441
sales@lifescienceindustryresearch.com
